相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Volumetric analysis of functional diffusion maps is a predictive imaging biomarker for cytotoxic and anti-angiogenic treatments in malignant gliomas
Benjamin M. Ellingson et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Validation of Functional Diffusion Maps (fDMs) as a Biomarker for Human Glioma Cellularity
Benjamin M. Ellingson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2010)
Utility of functional diffusion maps to monitor a patient diagnosed with gliomatosis cerebri
Benjamin M. Ellingson et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Tumor invasion after treatment of glioblastoma with bevacizumab: radiographic and pathologic correlation in humans and mice
John F. de Groot et al.
NEURO-ONCOLOGY (2010)
Infiltrative patterns of glioblastoma spread detected via diffusion MRI after treatment with cediranib
Elizabeth R. Gerstner et al.
NEURO-ONCOLOGY (2010)
A Vascular Normalization Index as Potential Mechanistic Biomarker to Predict Survival after a Single Dose of Cediranib in Recurrent Glioblastoma Patients
A. Gregory Sorensen et al.
CANCER RESEARCH (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy, safety and patterns of response and recurrence in patients with recurrent high-grade gliomas treated with bevacizumab plus irinotecan
R. M. Zuniga et al.
JOURNAL OF NEURO-ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Bevacizumab and chemotherapy for recurrent glioblastoma A single-institution experience
P. L. Nghiemphu et al.
NEUROLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Whitney B. Pope et al.
RADIOLOGY (2009)
Diffusion-Weighted Magnetic Resonance Imaging as a Cancer Biomarker: Consensus and Recommendations
[Anonymous]
NEOPLASIA (2009)
Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival
Daniel A. Hamstra et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas
Dieto Brandsma et al.
LANCET ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography:: A pilot study
Wei Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Effect of bevacizumab on radiation necrosis of the brain
Javier Gonzalez et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
The functional diffusion map: An imaging biomarker for the early prediction of cancer treatment outcome
Bradford A. Moffat et al.
NEOPLASIA (2006)
Evaluation of the functional diffusion map as an early biomarker of time-to-progression and overall survival in high-grade glioma
DA Hamstra et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Functional diffusion map: A noninvasive MR1 biomarker for early stratification of clinical brain tumor response
BA Moffat et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Quantitative comparison of algorithms for inter-subject registration of 3D volumetric brain MRI scans
BA Ardekani et al.
JOURNAL OF NEUROSCIENCE METHODS (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Reduction of eddy-current-induced distortion in diffusion MRI using a twice-refocused spin echo
TG Reese et al.
MAGNETIC RESONANCE IN MEDICINE (2003)